A Single-center, Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Injection of GenSci120 in Healthy Adult Participants in China
Latest Information Update: 04 Mar 2025
At a glance
- Drugs GenSci 120 (Primary)
- Indications Autoimmune disorders; Inflammatory bowel diseases; Rheumatoid arthritis; Sjogren's syndrome
- Focus Adverse reactions; Pharmacokinetics
- Sponsors GeneScience Pharmaceuticals
Most Recent Events
- 25 Feb 2025 Status changed from not yet recruiting to recruiting.
- 21 Feb 2025 New trial record